NZ754207A - 3-substituted propionic acids as alpha v integrin inhibitors - Google Patents

3-substituted propionic acids as alpha v integrin inhibitors

Info

Publication number
NZ754207A
NZ754207A NZ754207A NZ75420717A NZ754207A NZ 754207 A NZ754207 A NZ 754207A NZ 754207 A NZ754207 A NZ 754207A NZ 75420717 A NZ75420717 A NZ 75420717A NZ 754207 A NZ754207 A NZ 754207A
Authority
NZ
New Zealand
Prior art keywords
compounds
alpha
propionic acids
integrin inhibitors
substituted propionic
Prior art date
Application number
NZ754207A
Other languages
English (en)
Inventor
Guohua Zhao
Pratik Devasthale
Xiang-Yang Ye
Kumaravel Selvakumar
Suresh Dhanusu
Palanikumar Balasubramanian
Leatte R Guernon
Rita Civiello
Xiaojun Han
Michael F Parker
Swanee E Jacutin-Porte
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NZ754207A publication Critical patent/NZ754207A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ754207A 2016-11-08 2017-11-07 3-substituted propionic acids as alpha v integrin inhibitors NZ754207A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662418848P 2016-11-08 2016-11-08
PCT/US2017/060376 WO2018089353A1 (en) 2016-11-08 2017-11-07 3-substituted propionic acids as alpha v integrin inhibitors

Publications (1)

Publication Number Publication Date
NZ754207A true NZ754207A (en) 2025-09-26

Family

ID=60409432

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ754207A NZ754207A (en) 2016-11-08 2017-11-07 3-substituted propionic acids as alpha v integrin inhibitors

Country Status (30)

Country Link
US (2) US10968219B2 (OSRAM)
EP (1) EP3538525B1 (OSRAM)
JP (1) JP7097358B2 (OSRAM)
KR (1) KR102505629B1 (OSRAM)
CN (1) CN110167935B (OSRAM)
AR (1) AR110153A1 (OSRAM)
AU (1) AU2017359023B2 (OSRAM)
CA (1) CA3042707A1 (OSRAM)
CL (1) CL2019001264A1 (OSRAM)
CO (1) CO2019005824A2 (OSRAM)
DK (1) DK3538525T3 (OSRAM)
EA (1) EA038164B1 (OSRAM)
ES (1) ES2925173T3 (OSRAM)
HR (1) HRP20220990T1 (OSRAM)
HU (1) HUE059708T2 (OSRAM)
IL (1) IL266473B (OSRAM)
LT (1) LT3538525T (OSRAM)
MA (1) MA46743A (OSRAM)
MX (1) MX380799B (OSRAM)
MY (1) MY199931A (OSRAM)
NZ (1) NZ754207A (OSRAM)
PE (1) PE20191647A1 (OSRAM)
PL (1) PL3538525T3 (OSRAM)
PT (1) PT3538525T (OSRAM)
RS (1) RS63483B1 (OSRAM)
SI (1) SI3538525T1 (OSRAM)
SM (1) SMT202200338T1 (OSRAM)
TW (1) TWI763733B (OSRAM)
WO (1) WO2018089353A1 (OSRAM)
ZA (1) ZA201903665B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
CN110167935B (zh) * 2016-11-08 2022-05-27 百时美施贵宝公司 作为αV整合素抑制剂的3-经取代的丙酸
BR112019009129A2 (pt) * 2016-11-08 2019-07-16 Bristol-Myers Squibb Company compostos mono e espirocíclicos contendo ciclobutano e azetidina como inibidores de alfa v integrina
US10851098B2 (en) * 2016-11-08 2020-12-01 Bristol-Myers Squibb Company Azole amides and amines as alpha v integrin inhibitors
CN110177787A (zh) 2016-12-29 2019-08-27 圣路易斯大学 整合素拮抗剂
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
KR102605460B1 (ko) 2017-02-28 2023-11-22 모픽 테라퓨틱, 인코포레이티드 αvβ6 인테그린 억제제
CN112805001B (zh) 2018-08-29 2024-07-23 莫菲克医疗股份有限公司 抑制αvβ6整联蛋白
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN119462635A (zh) 2018-10-30 2025-02-18 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
CN109824495B (zh) * 2019-02-02 2022-12-09 盐城师范学院 一种新型偶联反应在制备碳-碳键结构化合物中的应用
KR20220047323A (ko) 2019-08-14 2022-04-15 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound
TW202513065A (zh) * 2023-09-21 2025-04-01 美商莫菲克醫療股份有限公司 抑制人類整合素α５β１

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451790A1 (de) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
JP2001524481A (ja) 1997-11-26 2001-12-04 デュポン ファーマシューティカルズ カンパニー αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類
AU736026B2 (en) * 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
EP1105389A4 (en) * 1998-08-13 2001-10-17 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
US6855722B2 (en) 2001-01-29 2005-02-15 Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
MXPA05006727A (es) * 2002-12-20 2005-09-08 Pharmacia Corp Acidos heteroarilalcanoicos como antagonistas de receptor de integrina.
AU2003297409A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation Pyrazole compounds as integrin receptor antagonists derivatives
WO2006108040A1 (en) 2005-04-05 2006-10-12 Janssen Pharmaceutica, N.V. Substituted indoles and their use as integrin antagonists
TW200800999A (en) * 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
EP2049490A1 (en) * 2006-06-09 2009-04-22 Astra Zeneca AB N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
BR112012004562B1 (pt) 2009-09-04 2021-02-17 Basf Se processo para preparar 1-fenilpirazóis e composto
MX2012004995A (es) 2009-10-29 2012-10-03 Sirtris Pharmaceuticals Inc Piridinas biciclicas y analogos como moduladores de sirtuina.
ITFI20100019A1 (it) 2010-02-12 2011-08-13 Univ Firenze Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
WO2016134223A2 (en) 2015-02-19 2016-08-25 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
US10214522B2 (en) * 2015-03-10 2019-02-26 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
CN110167935B (zh) * 2016-11-08 2022-05-27 百时美施贵宝公司 作为αV整合素抑制剂的3-经取代的丙酸

Also Published As

Publication number Publication date
TW201823244A (zh) 2018-07-01
CL2019001264A1 (es) 2019-09-13
ES2925173T3 (es) 2022-10-14
JP7097358B2 (ja) 2022-07-07
MX2019005244A (es) 2019-08-05
US20210188847A1 (en) 2021-06-24
MX380799B (es) 2025-03-12
JP2019537594A (ja) 2019-12-26
RS63483B1 (sr) 2022-09-30
MA46743A (fr) 2019-09-18
CN110167935B (zh) 2022-05-27
PL3538525T3 (pl) 2022-09-12
EA038164B1 (ru) 2021-07-16
HUE059708T2 (hu) 2022-12-28
KR102505629B1 (ko) 2023-03-02
SMT202200338T1 (it) 2022-09-14
LT3538525T (lt) 2022-09-26
EP3538525B1 (en) 2022-06-22
WO2018089353A1 (en) 2018-05-17
SI3538525T1 (sl) 2022-09-30
EP3538525A1 (en) 2019-09-18
HRP20220990T1 (hr) 2022-11-11
TWI763733B (zh) 2022-05-11
IL266473A (en) 2019-07-31
US10968219B2 (en) 2021-04-06
AR110153A1 (es) 2019-02-27
IL266473B (en) 2022-06-01
DK3538525T3 (da) 2022-08-29
EA201991122A1 (ru) 2019-10-31
AU2017359023A1 (en) 2019-06-20
PT3538525T (pt) 2022-08-16
CA3042707A1 (en) 2018-05-17
PE20191647A1 (es) 2019-11-07
MY199931A (en) 2023-11-29
ZA201903665B (en) 2022-12-21
AU2017359023B2 (en) 2021-12-09
CN110167935A (zh) 2019-08-23
CO2019005824A2 (es) 2019-06-11
KR20190073554A (ko) 2019-06-26
US11884661B2 (en) 2024-01-30
US20190263808A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MY199931A (en) 3-substituted propionic acids as alpha v integrin inhibitors
EA201991127A1 (ru) ЦИКЛОБУТАН- И АЗЕТИДИНСОДЕРЖАЩИЕ МОНО- И СПИРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНА αV
MX2019005234A (es) Amidas y aminas de azol como inhibidores de integrina alfa v.
MX378565B (es) Derivados de indazol como antagonistas de integrina alfa v.
EA201991124A1 (ru) ПИРРОЛЬНЫЕ АМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНОВ αV
PH12020500195A1 (en) Pyrimidinones as factor xia inhibitors
PH12017501586A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
PH12016501440A1 (en) Novel heterocyclic compounds
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
MY190429A (en) Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
WO2015200680A3 (en) Prmt5 inhibitors and uses thereof
MX2016010056A (es) 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
WO2017177004A8 (en) Tertiary amides and method of use
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
MX2017003458A (es) Indazol ureas y metodo de uso.
NZ743308A (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
TH170796A (th) พิริมิดีนในฐานะเป็นตัวยับยั้งแฟคเตอร์ xia